Publication Details

AFRICAN RESEARCH NEXUS

SHINING A SPOTLIGHT ON AFRICAN RESEARCH

medicine

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC) +Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Clinical Infectious Diseases, Volume 76, No. 8, Year 2023

Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/ efavirenz (EFV) for 192 weeks were then switched to TDF/ lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin.

Statistics
Citations: 15
Authors: 9
Affiliations: 3
Identifiers
Doi: 10.1093/cid/ciac949
ISSN: 10584838
e-ISSN: 15376591
Research Areas
Noncommunicable Diseases

Disclaimer

All information and calculations provided are based on our current indexed publications and may change as more data is collected.

African Research Nexus

The African Research Nexus is a visionary initiative that seeks to increase the visibility of African Researchers and Institutions. We are a dynamic hub designed to transform the African research landscape and amplify the voices of our continent’s brightest minds.

Useful Links

ABOUT US
PROFILES
Authors Directory
AI Digest
CONTACT US

Subscribe Now
Don’t miss our future updates!

Follow Us